Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

ABSTRACT: Human epidermal growth factor receptor 2-positive breast cancer (HER2+BC) is a common malignancy that is prone to recurrence and metastasis in the early stages, resulting in a poor prognosis for patients. Many studies have suggested that targeted therapy promotes clinical outcomes in HER2+BC. With the introduction of trastuzumab in 1998, the prognosis of patients with early HER2+BC has improved significantly. However, owing to obstinate drug resistance and adverse events, the addition of new agents in standardized treatment has become a research hotspot. These promising agents include antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and anti-HER2 combined therapies. This article provides a brief description of the biology of BC and the expression of HER2, with the aim to p

SUBMITTER: Xie J 

PROVIDER: S-EPMC9067050 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature